What can we achieve by implementing a compliance-improvement program?

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 1, 1997, Pages

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; Compliance; Medication; Prelapse; Schizophrenia

Indexed keywords

CONFERENCE PAPER; EDUCATION; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PREVENTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE;

EID: 0030942454     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199702001-00007     Document Type: Conference Paper

References (21)

1. Bauml J, Kissling W, Buttner P, et al. (1993) Central information and classification for improving compliance in patients with schizophrenic psychoses [in German]. Verhaltenstherapie 3 (suppl 1):1-96.
2. Bland RC, Parker JH, Orn H (1976) Prognosis in schizophrenia: a ten year follow-up of first admissions. Arch Gen Psychiatry 33:949-954.
3. Carpenter WT, Hanlon TE, Heinrichs DW, et al. (1990) Continuous versus targeted medication in schizophrenic out-patients: outcome results. Am J Psychiatry 147:1138-1148.
4. Drake R, Gates C, Cotton P, et al. (1984) Suicide among schizophrenics: who is at risk? J Nerv Ment Dis 172:613-617.
5. Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 52:173-188.
6. Glazer WM, Kane JM (1992) Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 53:426-433.
7. Herz MI, Melville CH (1980) Relapse in schizophrenia. Am J Psychiatry 137:801-805.
8. Herz MI, Glazer WM, Moster MA, et al. (1991) Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 48:333-339.
9. Jeste DV, Potkin SG, Sinha S, et al. (1979) Tardive dyskinesia reversible and persistent. Arch Gen Psychiatry 36:585-590.
10. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 301:837-842.
11. Jolley AG, Hirsch SR, McRink A, Manchanda R (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 298: 985-990.
12. Kane JM (1995) Tardive dyskinesia: epidemiological and clinical presentation. In: Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; pp 1485-1495.
13. Kane JM, Woerner M, Safferman A, et al. (1993) Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327-330.
14. Kissling W (ed) (1991) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin: Springer-Verlag.
15. Kissling W (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 89 (suppl 382):16-24.
16. May PRA, Tuma AH, Dixon WJ (1981) Schizophrenia: a follow-up study of five forms of treatment. Arch Gen Psychiatry 38:776-784.
17. Miles P (1977) Conditions predisposing to suicide: a review. J Nerv Ment Dis 164:231-246.
18. Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry 50:723-733.
19. Pietzcker A, Gaebel W, Kopcke W, et al. (1993) Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia. J Psychiatr Res 27:321-339.
20. Pietzcker A, Gaebel W, Kopcke W, Linden M, Moller P, Müller-Spahn F (1993) Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 163 (suppl 21):8-12.
21. Schooler NR, Keith SJ, Severe JB, et al. (1997) Relapse and rehospitalization during maintenance treatment of schizphrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry (in press).